Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.

7/23/24 8:38:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AIMD alert in real time by email

The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.

This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025.

SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"), today announced it has enrolled the first subject for its Taiwanese clinical study of VELDONA®-based animal drug in treating feline chronic gingivostomatitis ("FCGS"), a serious and painful chronic cat oral disease characterized by inflammation or abnormal proliferation in the oral cavity. Dosing of the first subject is expected to occur on July 26, 2024.

Get the next $AIMD alert in real time by email

Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.

Chat with this insight

Recent Analyst Ratings for
$AIMD

$AIMD
Press Releases

Fastest customizable press release news feed in the world

Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments

Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

$AIMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by Ainos Inc.

Amendment: SEC Form SC 13D/A filed by Ainos Inc.

SEC Form SC 13D/A filed by Ainos Inc. (Amendment)

$AIMD
SEC Filings

$AIMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 10-Q filed by Ainos Inc.

Ainos Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Ainos Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Director Tsai Chun-Jung was granted 4,200 shares, increasing direct ownership by 4% to 115,103 units (SEC Form 4)

CEO, PRESIDENT, CHAIRMAN Tsai Chun-Hsien was granted 3,000 shares, increasing direct ownership by 0.94% to 322,830 units (SEC Form 4)

Director Lee Ting-Chuan was granted 4,200 shares, increasing direct ownership by 4% to 122,711 units (SEC Form 4)

$AIMD
Market Insights

Live Market Insights